Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.36 |
| ▸ | AXL | P30530 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 7/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.35 |
| ▸ | FLT3 | P36888 | 6/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3004803 | 0.75 | NOS1 (0.40) | NOS1AXLCDK2CCNA1IDO1 | |
| SCHEMBL19511770 | 0.73 | SRC (0.46) | SRC | |
| SCHEMBL20002212 | 0.72 | CDK2 (0.47) | NOS1AXLCDK2CCNA1FLT3 | |
| SCHEMBL180561 | 0.72 | HTR1D (0.39) | SRCPARP1TNK1 | |
| SCHEMBL3201541 | 0.71 | TRPV1 (0.34) | NOS1AXLCDK2CCNA1FLT3 | |
| SCHEMBL27139628 | 0.69 | MAPT (0.37) | NOS1FLT3KDRSRCPARP1 | |
| SCHEMBL19118540 | 0.69 | IDO1 (0.40) | NOS1AXLCDK2CCNA1FLT3 | |
| SCHEMBL12321248 | 0.69 | NOS1 (0.56) | NOS1AXLCDK2CCNA1IDO1 | |
| SCHEMBL31712925 | 0.68 | SRC (0.33) | SRC | |
| SCHEMBL6725176 | 0.67 | CXCR4 (0.40) | SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071156-B2 | Aqueous gel formulations containing immune response modifiers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-09-11 | — | — | US | claimed |
| US-20160101173-A1 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS | 3M INNOVATIVE PROPERTIES CO (US) | 2016-04-14 | — | — | US | claimed |
| US-9248127-B2 | Aqueous gel formulations containing immune response modifiers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-02-02 | — | — | US | claimed |
| US-20090163532-A1 | Aqueous Gel Formulations Containing Immune Response Modifiers | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-06-25 | — | — | US | claimed |
| EP-1844201-A2 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-10-17 | — | — | EP | claimed |
| WO-2006084251-A2 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE REPONSE MODIFIERS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| US-20240173390-A1 | PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | THE U.S.A, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-05-30 | — | — | US | disclosed |
| CN-118103059-A | Self-assembled nanoparticles based on amphiphilic peptides | 巴林萨斯生物疗法北美公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2024092030-A1 | SELF-ASSEMBLING NANOPARTICLES | VACCITECH NORTH AMERICA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024092028-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | VACCITECH NORTH AMERICA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-4355367-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES FOR DRUG DELIVERY APPLICATIONS | Barinthus Biotherapeutics North America, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-11938177-B2 | Peptide vaccine formulations and use thereof for inducing an immune response | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-03-26 | — | — | US | disclosed |
| EP-4294431-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES | Vaccitech North America, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20060045885-A1 | Method of eliciting an immune response against HIV | GOVERNMENT OF THE UNITED STRATS OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE | 2006-03-02 | — | — | US | disclosed |
| US-20060045886-A1 | HIV immunostimulatory compositions | 3M INNOVATIVE PROPERTIES COMPANY | 2006-03-02 | — | — | US | disclosed |
| WO-2006007491-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20050267145-A1 | Treatment for lung cancer | COLEY PHARMACEUTICAL GROUP, INC. | 2005-12-01 | — | — | US | disclosed |
| US-20050226878-A1 | Therapeutic combinations and methods including IRM compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2005-10-13 | — | — | US | disclosed |
| EP-0506709-A1 | ARTHROPODICIDAL PYRAZOLINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-07 | — | — | EP | disclosed |
| WO-1991008207-A1 | ARTHROPODICIDAL PYRAZOLINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173390-A1 | PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | NGLY1, MYD88, SPPL2B | NOS1 3307/4885AXL 1492/4885CDK2 4452/4885 |
| US-20060045886-A1 | HIV immunostimulatory compositions | CD4, ICOS, CXCL10 | NOS1 2672/4885AXL 2372/4885CDK2 4620/4885 |
| US-10071156-B2 | Aqueous gel formulations containing immune response modifiers | IFNG, ICOS, IL4 | NOS1 405/4885AXL 1108/4885CDK2 838/4885 |
| US-11938177-B2 | Peptide vaccine formulations and use thereof for inducing an immune response | NGLY1, MYD88, SPPL2B | NOS1 3307/4885AXL 1492/4885CDK2 4452/4885 |
| US-20090163532-A1 | Aqueous Gel Formulations Containing Immune Response Modifiers | IFNG, ICOS, IL4 | NOS1 405/4885AXL 1108/4885CDK2 838/4885 |
| US-20160101173-A1 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS | IFNG, ICOS, IL4 | NOS1 405/4885AXL 1108/4885CDK2 838/4885 |
| US-20060045885-A1 | Method of eliciting an immune response against HIV | CD69, IRF3, CD4 | NOS1 3183/4885AXL 4538/4885CDK2 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.